Mircury lna mirna power inhibitor control

GW0742 (25, 100 and 400 μg/kg, Tocris, USA) or vehicle (1% DMSO diluted in corn oil) were administered intranasally^{27 (link)} at 1 and 24 h after HI. 2 μl of GW0742 per drop was given every 2 min in alternating nares. PPAR-β/δ antagonist GSK3787 (300 μg/kg, Abcam, USA) or vehicle (1% DMSO diluted in corn oil) were administered intranasally at 1 h before HI and at 24 h post HI. 0.5 nmol of LNA miR-17-5p inhibitor (antimiR, rno-miR-17-5p miRCURY LNA miRNA Power Inhibitor, Exiqon) or control (miRCURY LNA miRNA Power Inhibitor Control, Exiqon) were administered via intracerebroventricular injection^{28 (link)} at 1.5 mm posterior, 1.5 mm lateral to the bregma and 2.5 mm deep on the ipsilateral hemisphere at 24 h before HI. A total of 2 μl of antimiR per pup was injected slowly in 5 min. The needle was left in place for an additional 10 min and then slowly withdrawn over 5 min to prevent backflow. Intranasal route of administration was also tested - 200 pmol of miR-17-5p-LNA inhibitor or same dose of LNA scramble control in 10 μl saline were delivered into each naris at 24 h before HI. 1 μg of TXNIP CRISPR activation plasmid (Santa Cruz, USA) or control CRISPR Activation Plasmid (Santa Cruz, USA) were administered via intracerebroventricular injection to the ipsilateral hemisphere at 48 h pre HI. 2μl drug per pup was injected slowly in 5 min.